PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
10.76%
EBIT growth similar to CRVO's 10.20%. Walter Schloss might infer both firms share similar operational efficiencies.
10.76%
Operating income growth under 50% of CRVO's 189.80%. Michael Burry would be concerned about deeper cost or sales issues.
11.35%
Net income growth 1.25-1.5x CRVO's 9.19%. Bruce Berkowitz would see if strategic cost cutting or product mix explains this difference.
31.03%
EPS growth 1.25-1.5x CRVO's 22.20%. Bruce Berkowitz would check if strategic initiatives like cost cutting or better capital management explain the difference.
31.72%
Diluted EPS growth 1.25-1.5x CRVO's 22.20%. Bruce Berkowitz would verify if strategic moves (e.g., targeted acquisitions, cost cuts) explain the edge.
29.31%
Share count expansion well above CRVO's 16.72%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
29.44%
Diluted share count expanding well above CRVO's 16.72%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
2.31%
OCF growth 1.25-1.5x CRVO's 1.78%. Bruce Berkowitz would see if superior pricing or efficient operations explain the gap.
3.06%
FCF growth above 1.5x CRVO's 1.78%. David Dodd would verify if the firm’s strategic investments yield superior returns.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-254578.19%
Negative 10Y OCF/share CAGR while CRVO stands at 99.40%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
64.50%
5Y OCF/share CAGR at 50-75% of CRVO's 98.79%. Martin Whitman would question if the firm lags in monetizing revenue effectively.
73.57%
3Y OCF/share CAGR at 75-90% of CRVO's 84.15%. Bill Ackman would press for improvements in margin or overhead to catch up.
-9976.84%
Negative 10Y net income/share CAGR while CRVO is at 99.67%. Joel Greenblatt sees a major red flag in long-term profit erosion.
-124.34%
Negative 5Y net income/share CAGR while CRVO is 98.78%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
76.73%
3Y net income/share CAGR 75-90% of CRVO's 88.62%. Bill Ackman might push for an operational plan to match or beat the competitor’s short-term growth.
1493.31%
Positive growth while CRVO is negative. John Neff might see a strong advantage in steadily compounding net worth over a decade.
-38.28%
Both show negative equity/share growth mid-term. Martin Whitman suspects cyclical or structural challenges for each company.
-74.77%
Both show negative short-term equity/share CAGR. Martin Whitman suspects an industry slump or unprofitable expansions for both players.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
78.33%
Asset growth above 1.5x CRVO's 18.40%. David Dodd checks if M&A or new capacity expansions are value-accretive vs. competitor's approach.
127.26%
BV/share growth above 1.5x CRVO's 6.99%. David Dodd confirms if consistent profit retention or fewer write-downs yield faster equity creation.
-9.95%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
-7.53%
Both reduce R&D yoy. Martin Whitman sees an industry shifting to cost reduction or limited breakthroughs in the near term.
-21.01%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.